Sign in
Taking peoplePhase 3

Testing AZD6234 for Adults With Type 2 Diabetes and Excess Weight

Tests AZD6234 against placebo in adults with type 2 diabetes and excess weight.

Key facts

Who runs it
AstraZeneca
Where
Busan, Daegu, Daejeon, Incheon, Seoul, and Suwon, South KoreaSee the 6 sitesAlso in 15 other countries, 184 sites
Registry title
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
Status
Recruiting
Phase
Phase 3
People taking part
1,500 people, planned
Started
20 Aug 2026
Expected to end
9 Aug 2028
Type of study
Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Lenbelintide
  • Placebo
Record updated
28 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with type 2 diabetes who also have overweight or obesity. It compares AZD6234 with placebo for weight change over 68 weeks.

Age
18 years or older
Sex
All sexes and gender identities can join.
Disease stage
Type 2 diabetes diagnosed at least 90 days before screening, with BMI of 27 kg/m2 or more and HbA1c between 6.0% (42 mmol/mol) and 10% (86 mmol/mol).
Earlier treatment
Diabetes managed with diet and exercise alone, or with a stable dose of an oral glucose-lowering medicine. Stable body weight (5% change or less) for at least 3 months. At least one self-reported unsuccessful attempt to lose weight. No GLP-1 medicine in the 3 months before randomisation. No insulin for type 2 diabetes in the 3 months before screening.
Biomarker or test result
HbA1c of 6.0% (42 mmol/mol) to 10% (86 mmol/mol) at screening.

Main reasons for not taking part

  • Obesity mainly caused by another hormone disorder
  • Type 1 diabetes or diabetes that is not clearly type 2
  • Ketoacidosis or hyperosmolar coma/state in the 3 months before screening
  • Significant liver or bile duct disease, or ALT or AST of 3.0 X ULN or more, or TBL above 1.5 X ULN
  • GLP-1 medicine in the 3 months before randomisation

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Males \& females (inclusive of all gender identities) age ≥18 years
  • BMI ≥27 kg/m2
  • Diagnosed with T2DM ≥90 days prior to Screening
  • HbA1c value at Screening of ≥6.0% (42 mmol/mol) and ≤10% (86 mmol/mol) managed with diet and exercise alone or with a stable dose of any oral glycaemic-lowering agent (as per local labelling)
  • Stable body weight (≤5% body weight change) for at least 3 months prior to Randomisation
  • History of at least one self-reported unsuccessful attempt to lose body weight in lifetime

Who cannot take part

  • Type 1 diabetes mellitus (or any other diabetes mellitus that is not clearly Type 2 diabetes), OR have history of ketoacidosis or hyperosmolar coma/state within 3 months prior to Screening
  • Has received treatment with a GLP-1 receptor agonist or GLP-1 containing medication for any indication within 3 months before Randomisation
  • Use of insulin therapy for T2DM within 3 months prior to screening
  • Obesity primarily caused by other endocrine disorders
  • Significant hepatobiliary disease and/or any of the following results at Screening:; ALT ≥ 3.0 X ULN; AST ≥ 3.0 X ULN; TBL > 1.5 X ULN (except for cases of known Gilbert's Syndrome)

Where in South Korea

Also in 15 other countries, 184 sites

  • BusanHospital not named in the registryNot yet recruiting
  • DaeguHospital not named in the registryNot yet recruiting
  • DaejeonHospital not named in the registryNot yet recruiting
  • IncheonHospital not named in the registryNot yet recruiting
  • SeoulHospital not named in the registryNot yet recruiting
  • SuwonHospital not named in the registryNot yet recruiting

About the trial

What the trial wants to find out

The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment

The 3 groups in the trial

  • AZD6234 Dose 1Treatment being tested

    Treatment: Lenbelintide

  • AZD6234 Dose 2Treatment being tested

    Treatment: Lenbelintide

  • PlaceboPlacebo, for comparison

    Matching placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase III Randomized, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Type 2 Diabetes Mellitus and Obesity or Overweight (SELENE 2)
Plain-language title
Testing AZD6234 for Adults With Type 2 Diabetes and Excess WeightGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
28 October 2026